|
Xarelto and other warfarin alternatives about to hit the U.S. market. |
 |
|
...
Fierce Pharma: Several more potential rivals for warfarin are in clinical trials. And even if all of them finally get onto the market, there could be space for them to fight over market share. That's because warfarin is a tricky drug to administer; even though it's available in generic form, doctors may turn to this new generation of meds instead; one analyst put the potential market at $14 billion. "[E]xpect all of the polite reticence that has been developing around direct-to-consumer advertising to fade" as the newcomers try to outdo one another, Matthew Herper writes. |